Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2657-2664

  Chan, Arlene ^a   Conte, Pier Franco ^b   Petruzelka, Lubos ^c   Tubiana Mathieu, Nicole ^d   Ganju, Vinod ^e   Llombart, Antonio ^f   Espie, Marc ^g   Majois, Françoise ^h   Gil, Miguel Gil ⁱ   Vaissiere, Nathalie ^j   Villanova, Gustavo ^j  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c CHARLES UNIVERSITY   (Czech Republic)

^d DUPUYTREN UNIVERSITY HOSPITAL   (France)

^e FRANKSTON HOSPITAL   (Australia)

^f Oncological Institute of Valencia   (Spain)

^g SAINT LOUIS HOSPITAL   (France)

^h Hospital de Jolimont   (Belgium)

ⁱ Radiation Oncology Department   (Spain)

^j INSTITUT DE RECHERCHE PIERRE FABRE   (France)

more..

Author keywords

First line; HER2 positive; Metastatic breast cancer; Oral chemotherapy

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; ERBB2 PROTEIN, HUMAN; FLUOROURACIL; MONOCLONAL ANTIBODY; VINBLASTINE;

ADULT; AGE DISTRIBUTION; ALOPECIA; ANEMIA; BREAST METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VOMITING; AGED; ARTICLE; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; FIRST-LINE; HER2-POSITIVE; METABOLISM; METASTASIS; MIDDLE AGED; ORAL CHEMOTHERAPY; SURVIVAL RATE; VERY ELDERLY;

FIRST-LINE; HER2-POSITIVE; METASTATIC BREAST CANCER; ORAL CHEMOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; SURVIVAL RATE; VINBLASTINE;

MLCS; MLOWN;

EID: 84881343799     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. De Vita V Jr., Lawrence T and Rosenberg S: Principles and Practice of Oncology, 9th edition. p. 1442, Lippincott, Williams and Wilkins, 2011.
2. Sledge G, Cardoso F, Winer E and Piccart M: A Dickens tale of the treatment of advanced breast cancer: The past, the present, and the future. ASCO Educational Book pp. 28-38, 2012.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer: Version 2.2012.
4. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz P, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I and Winer E: First international consensus guidelines for advanced breast cancer (ABC1). Breast 3: 242-252, 2012.
5. Pegram M, Konecny G, O'Callaghan C, Beryt M, Pietras R and Slamon D: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Can Inst 96: 739-749, 2004.
6. Chan A, Martin M, Untch M, Gil MG, Guillem Porta V, Wojtukiewicz M, Kellokumpu-Lehtinen P, Sommer HL, Georgoulias V, Battelli N, Pawlicki M, Aubert D, Bourlard T, Gasmi J, Villanova G and Petruzelka L: Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 95: 788-93, 2006.
7. Chan A: A review of the use of trastuzumab plus vinorelbine in metastatic breast cancer. Ann Oncol 18: 1152-1158, 2007.
8. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen A, Karlsson P, Tange U, Sorensen P, Moller S, Bergh J and Langkjer S: Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced HER2-positive breast cancer: the HERNATA study. J Clin Oncol 29: 3, 264-271, 2011.
9. Bernardo G, Palumbo R, Bernardo A, Poggi G, Delmonte A, Teragni C, Frascaroli M, Jedrychowska I, Canto A and Strada M: Trastuzumab plus intravenous or oral vinorelbine in chemonaive patients with HER-2 overexpressing metastatic breast cancer: Final results of an extended phase II trial. Eur J Cancer Supplements 6: 7 (abstract 168), 2006.
10. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Bachleitner-Hoffmann T, Locker G, Rudas M, Mader R, Zielinski C and Steger G: Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat 102: 375-381, 2007.
11. Illarramendi J, Blancas I, Bueso P, Carabantes F, Polo Marques E, Ciruelos Gil E, Corral M and Perez F: Oral vinorelbine in combination with trastuzumab in metastatic breast cancer: Data on efficacy and safety when administered in first or second line setting. J Clin Oncol 28: 15S (abstract e11508), 2010.
12. Heinemann V, Di Gioia D, Vehling-Kaiser U, Harich H, Heinrich B, Welt A, Ziske C, Deutsch G, Pihusch R, Kolbl H, Hegewisch-Becker S, Michl M and Stemmler H: A prospective, multicenter phase II study of oral and intravenous vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol 22: 603-608, 2011.
13. Ershler W: Capecitabine monotherapy: Safe and effective treatment for metastatic breast cancer. Oncologist 11: 325-335, 2006.
14. Fujimoto-Ouchi K, Sekiguchi F and Tanaka Y: Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 49: 211-216, 2002.
15. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader R, Gnant M, Zielinski C and Steger G: Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25: 3853-3858, 2007.
16. Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg H, Lakner V, Hinke A and Bangemann N: Phase II study of capecitabine and trastuzumab in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 25: 3246-3250, 2007.
17. Yamamoto D, Iwase S, Kitamura K, Odagiri H, Yamamoto C and Nagumo Y: A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Research Network (JBCRN) 00 trial. Cancer Chemother Pharmacol 61: 509-514, 2008.
18. Sawada N, Fujimoto-Ouchi K, Ishikawa T, Tanaka Y and Ishituka H: Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res (abstract 5388), 2002.
19. Tubiana Mathieu N, Bougnoux P, Becquart D, Chan A, Conte P, Majois F, Espie M, Morand M, Vaissiere N and Villanova G: All-oral combination of vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an international phase II trial. Br J Cancer 101: 232-237, 2009.
20. Finek J, Holubec L Jr., Svoboda T, Sefrhansova L, Pavlikova I, Votavova M, Sediva M, Filip S, Kosevnikova R and Kormunda S: A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res 29: 667-670, 2009.
21. Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M and Goldhirsch A: Phase II study of an all-oral regimen combining oral vinorelbine with capecitabine as first-line chemotherapy of metastatic breast cancer. Cancer Chemother Pharmacol 64: 673-680, 2009.
22. Campone M, Dobrovolskaya N, Tjulandin S, Chen S, Fourie S, Mefti F, Konstantinova M, Lefresne F, Meheust N and Jassem J: Final results of a three-Arm randomised phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. The Breast Journal 19: 240-49, 2013.
23. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom A, Christian M and Gwyther S: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
24. Fleming TR: One sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151, 1982.
25. Le Brun-Ly L, Martin J, Venat-Bouvet L, Darodes N, Labourey J, Genet D and Tubiana-Mathieu N: Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity. Oncology 76: 322-325, 2009.
26. Burris H, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco F, White M and Hainsworth J: Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as firstline treatment for patients with metastatic breast cancer. J Clin Oncol 22: 1621-1629, 2004.
27. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K and Extra J: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274, 2005.
28. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L and Slamon D: Randomized phase II study of trastuzumab, paclitaxel and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24: 2786-2792, 2006.
29. Palumbo R, Bernardo A, Strada M, Poggi G, Teragni C, Amatu A, Frascaroli M, Montagna B, Sottotetti F and Bernardo G: Triple combination of 3-weekly trastuzumab plus oral vinorelbine and capecitabine as first-line treatment in HER2-positive metastatic breast cancer: An active and well-tolerated regimen that allows patient compliance. Eur J Cancer Supplements 7(2) (abstract 5081), 2009.
30. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
31. Liu G, Franssen E, Fitch M and Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115, 1997.
32. Findlay M, Von Minckwitz G and Wardley A: Effective oral chemotherapy for breast cancer: Pillars of strength. Ann Oncol 19: 212-222, 2008.
33. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B and Jackisch C: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): A phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13: 869-78, 2012.